Triggering receptor expressed on myeloid cells receptor family modulators: A patent review

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 12, 2014, Pages 1383-1395

  Pelham, Christopher J ^a   Pandya, Amit N ^a   Agrawal, Devendra K ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD177; DNAX activation protein of 12 kDa; Heat shock protein 60; High mobility group box 1; Immunomodulator; Peptidoglycan recognition protein 1; Toll like receptor; TREM like transcript; Triggering receptor expressed on myeloid cells

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CD177 LIGAND; CHAPERONIN 60; HIGH MOBILITY GROUP B1 PROTEIN; MEMBRANE RECEPTOR; PEPTIDOGLYCAN RECOGNITION PROTEIN; PEPTIDOGLYCAN RECOGNITION PROTEIN 1; SOLUBLE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 DECOY RECEPTOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 DECOY RECEPTOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 3; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 4; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS LIKE TRANSCRIPT RECEPTOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS TRANSCRIPT 2 RECEPTOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM-2A RECEPTOR; TREM-2B RECEPTOR; TREM1 PROTEIN, HUMAN; TREM3 PROTEIN, MOUSE; TREML1 PROTEIN, HUMAN; TREML4 PROTEIN, HUMAN;

ALZHEIMER DISEASE; BONE DYSPLASIA; BONE MARROW CELL; CARDIOVASCULAR DISEASE; DISEASE COURSE; GENE DELETION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; LEUKOENCEPHALOPATHY; LIGAND BINDING; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TREM LIKE TRANSCRIPT 1 DEFICIENCY; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 DEFICIENCY; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 DEFICIENCY; ANIMAL; DRUG EFFECTS; PHYSIOLOGY;

ANIMALS; HUMANS; MEMBRANE GLYCOPROTEINS; PATENTS AS TOPIC; RECEPTORS, IMMUNOLOGIC;

EID: 84911925679     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.977865     Document Type: Review

References (97)

1. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000;164(10):4991-5
2. Colonna M, Bouchon A. inventors Bioxell SpA, assignee. Novel receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof. US20100310560A1; 2010
3. Allcock RJ, Barrow AD, Forbes S, et al. The human TREM gene cluster at 6p21.1 encodes both activating and inhibitory single IgV domain receptors and includes NKp44. Eur J Immunol 2003;33(2):567-77
4. Daws MR, Lanier LL, Seaman WE, et al. Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. Eur J Immunol 2001;31(3):783-91
5. Lanier LL, Corliss BC, Wu J, et al. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998;391(6668):703-7
6. Takaki R, Watson SR, Lanier LL. DAP12: an adapter protein with dual functionality. Immunol Rev 2006;214:118-29
7. Clark GJ, Ju X, Tate C, et al. The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends Immunol 2009;30(5):209-17
8. Weber B, Schuster S, Zysset D, et al. TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance. PLoS Pathog 2014;10(1):e1003900
9. Klesney-Tait J, Keck K, Li X, et al. Transepithelial migration of neutrophils into the lung requires TREM-1. J Clin Invest 2013;123(1):138-49
10. Wu J, Li J, Salcedo R, et al. The proinflammatory myeloid cell receptor TREM-1 controls kupffer cell activation and development of hepatocellular carcinoma. Cancer Res 2012;72(16):3977-86
11. Sharif O, Gawish R, Warszawska JM, et al. The triggering receptor expressed on myeloid cells 2 inhibits complement component 1q effector mechanisms and exerts detrimental effects during pneumococcal pneumonia. PLoS Pathog 2014;10(6):e1004167
12. Turnbull IR, Gilfillan S, Cella M, et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 2006;177(6):3520-4
13. Kang H, Kim E. Kim D. et al.. inventors Industry Foundation of Chonnam National University, assignee. TREM-2 gene and protein as inhibitors of expression of GA733-2, and transgenic animals comprising the same and uses thereof. US20100299767A1; 2011
14. Washington AV, Schubert RL, Quigley L, et al. A TREM family member, TLT-1, is found exclusively in the alpha-granules of megakaryocytes and platelets. Blood 2004;104(4):1042-7
15. Washington AV, Gibot S, Acevedo I, et al. TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. J Clin Invest 2009;119(6):1489-501
16. Derive M, Bouazza Y, Sennoun N, et al. Soluble TREM-like transcript-1 regulates leukocyte activation and controls microbial sepsis. J Immunol 2012;188(11):5585-92
17. Bouchon A, Facchetti F, Weigand MA, et al. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001;410(6832):1103-7
18. Arts RJ, Joosten LA, Dinarello CA, et al. TREM-1 interaction with the LPS/TLR4 receptor complex. Eur Cytokine Netw 2011;22(1):11-14
19. Fortin CF, Lesur O. Fulop T, Jr. Effects of TREM-1 activation in human neutrophils: activation of signaling pathways, recruitment into lipid rafts and association with TLR4. Int Immunol 2007;19(1):41-50
20. Ornatowska M, Azim AC, Wang X, et al. Functional genomics of silencing TREM-1 on TLR4 signaling in macrophages. Am J Physiol Lung Cell Mol Physiol 2007;293(6):L1377-84
21. Dower K, Ellis DK, Saraf K, et al. Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol 2008;180(5):3520-34
22. Kuai J, Dower K. Feldman J. et al.. inventors Wyeth, assignee. Inflammation treatment, detection and monitoring via TREM-1. US20080247955A1; 2008
23. Sharif O, Knapp S. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 2008;213(9-10):701-13
24. Chen LC, Laskin JD, Gordon MK, et al. Regulation of TREM expression in hepatic macrophages and endothelial cells during acute endotoxemia. Exp Mol Pathol 2008;84(2):145-55
25. Rigo I, McMahon L, Dhawan P, et al. Induction of triggering receptor expressed on myeloid cells (TREM-1) in airway epithelial cells by 1,25(OH)(2) vitamin D(3). Innate Immun 2012;18(2):250-7
26. Dimopoulou I, Pelekanou A, Mavrou I, et al. Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: correlation with monocyte gene expression. J Crit Care 2012;27(3):294-300
27. Gibot S, Cravoisy A, Levy B, et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004;350(5):451-8
28. Sigalov AB. A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock. Int Immunopharmacol 2014;21(1):208-19
29. Molad Y, Pokroy-Shapira E, Carmon V. CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding. Innate Immun 2013;19(6):623-30
30. Hosoda H, Tamura H, Kida S, et al. Transcriptional regulation of mouse TREM-1 gene in RAW264.7 macrophage-like cells. Life Sci 2011;89(3-4):115-22
31. Zeng H, Ornatowska M, Joo MS, et al. TREM-1 expression in macrophages is regulated at transcriptional level by NF-kappaB and PU.1. Eur J Immunol 2007;37(8):2300-8
32. Kim TH, Lee B, Kwon E, et al. Regulation of TREM-1 expression by 1,25-dihydroxyvitamin D3 in human monocytes/macrophages. Immunol Lett 2013;154(1-2):80-5
33. Bosco MC, Pierobon D, Blengio F, et al. Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood 2011;117(9):2625-39
34. Kelker MS, Foss TR, Peti W, et al. Crystal structure of human triggering receptor expressed on myeloid cells 1 (TREM-1) at 1.47 A. J Mol Biol 2004;342(4):1237-48
35. Radaev S, Kattah M, Rostro B, et al. Crystal structure of the human myeloid cell activating receptor TREM-1. Structure 2003;11(12):1527-35
36. Gomez-Pina V, Soares-Schanoski A, Rodriguez-Rojas A, et al. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharidestimulated human monocytes. J Immunol 2007;179(6):4065-73
37. Gingras M, Margolin J. inventors Bioprovar Corporation, assignee. TREM-1 splice variant for use in modifying immune responses. US20050180973A1; 2005
38. Kolopp-Sarda M, Bene M. Panina P. et al.. inventors Universite Henri Poincare Nancy I, assignee. Method of diagnosing infectious disease by measuring the level of soluble TREM-1 in a sample. US20070281319A1; 2007
39. Faure G, Gibot S, Panina P, et al. inventors Universite Henri Poincare Nancy I and Novo Nordisk AS, assignee. Therapeutic peptides and method. US20120015867A1. 2012
40. Gibot S, Kolopp-Sarda MN, Bene MC, et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 2004;200(11):1419-26
41. Gibot S, Buonsanti C, Massin F, et al. Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infect Immun 2006;74(5):2823-30
42. Wong-Baeza I, Gonzalez-Roldan N, Ferat-Osorio E, et al. Triggering receptor expressed on myeloid cells (TREM-1) is regulated post-transcriptionally and its ligand is present in the sera of some septic patients. Clin Exp Immunol 2006;145(3):448-55
43. Haselmayer P, Grosse-Hovest L, von Landenberg P, et al. TREM-1 ligand expression on platelets enhances neutrophil activation. Blood 2007;110(3):1029-35
44. Mariani M, Sinigaglia F, Panina P. inventors BioXell SpA, assignee. Diagnostic and prognostic compounds and method. US20060183125A1; 2006
45. Colonna M, Klesney-Tait J, Panina P. inventors Bioxell SpA, assignee. Screening, therapy and diagnosis. US20100306863A1; 2010
46. Kissel K, Santoso S, Hofmann C, et al. Molecular basis of the neutrophil glycoprotein NB1 (CD177) involved in the pathogenesis of immune neutropenias and transfusion reactions. Eur J Immunol 2001;31(5):1301-9
47. Sachs UJ, Andrei-Selmer CL, Maniar A, et al. The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD31). J Biol Chem 2007;282(32):23603-12
48. Stennicke V, Read C, Grell S, et al. inventors Novo Nordisk AS, assignee. Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1). US20130211050A1; 2013
49. Stennicke V, Read C. Kuijper J, et al., inventors; Novo Nordisk AS, assignee. Antibodies that bind peptidoglycan recognition protein 1. WO2013120554A1; 2013
50. Oyston PC, Fox MA, Richards SJ, et al. Novel peptide therapeutics for treatment of infections. J Med Microbiol 2009;58(Pt 8):977-87
51. Bopp C, Bierhaus A, Hofer S, et al. Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 2008;12(1):201
52. Sigalov AB. Immune cell signaling: a novel mechanistic model reveals new therapeutic targets. Trends Pharmacol Sci 2006;27(10):518-24
53. Sigalov A. inventor Signablok Inc, assignee. Inhibition of TREM receptor signaling with peptide variants. US20120202733A1; 2012
54. N'Diaye EN, Branda CS, Branda SS, et al. TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J Cell Biol 2009;184(2):215-23
55. Humphrey MB, Daws MR, Spusta SC, et al. TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J Bone Miner Res 2006;21(2):237-45
56. Paloneva J, Manninen T, Christman G, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 2002;71(3):656-62
57. Kaifu T, Nakahara J, Inui M, et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest 2003;111(3):323-32
58. Kikutani H, Kumanogoh A, Sugiyama K. inventors Boehringer Ingelheim Int, assignee. Methods for treating inflammatory, autoimmune or bone resorption diseases. CA2551163A1; 2008
59. Takegahara N, Takamatsu H, Toyofuku T, et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat Cell Biol 2006;8(6):615-22
60. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in alzheimer's disease. N Engl J Med 2013;368(2):117-27
61. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of alzheimer's disease. N Engl J Med 2013;368(2):107-16
62. Stefansson H, Jonsson T, Steinberg S. inventors Illumina Inc and Decode Genetics EHF, assignee. Risk variants of alzheimer's disease. WO2014074942A1; 2014
63. Chen Q, Zhang K, Jin Y, et al. Triggering receptor expressed on myeloid cells-2 protects against polymicrobial sepsis by enhancing bacterial clearance. Am J Respir Crit Care Med 2013;188(2):201-12
64. Tojo H, Henta T, Sasada R. inventors Takeda Pharmaceutical Company Ltd, assignee. Insulin resistance improving agents. US20060014679A1; 2006
65. Pelham CJ, Agrawal DK. Emerging roles for triggering receptor expressed on myeloid cells receptor family signaling in inflammatory diseases. Expert Rev Clin Immunol 2014;10(2):243-56
66. Daws MR, Sullam PM, Niemi EC, et al. Pattern recognition by TREM-2: binding of anionic ligands. J Immunol 2003;171(2):594-9
67. Ito H, Hamerman JA. TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells. Eur J Immunol 2012;42(1):176-85
68. Hamerman JA, Jarjoura JR, Humphrey MB, et al. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 2006;177(4):2051-5
69. Senn J. inventor Isis Pharmaceuticals Inc, assignee. Proinflammatory nucleic acids. US20120295272A1; 2012
70. Stefano L, Racchetti G, Bianco F, et al. The surface-exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor. J Neurochem 2009;110(1):284-94
71. Chung DH, Seaman WE, Daws MR. Characterization of TREM-3, an activating receptor on mouse macrophages: definition of a family of single ig domain receptors on mouse chromosome 17. Eur J Immunol 2002;32(1):59-66
72. Colonna M, Panina P. inventors Bioxell SpA, assignee. Novel receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof. US20060263770A1; 2006
73. Jin S, Umemoto E, Tanaka T, et al. Nepmucin/CLM-9, an ig domain-containing sialomucin in vascular endothelial cells, promotes lymphocyte transendothelial migration in vitro. FEBS Lett 2008;582(20):3018-24
74. Watarai H, Sekine E, Inoue S, et al. PDC-TREM, a plasmacytoid dendritic cell-specific receptor, is responsible for augmented production of type I interferon. Proc Natl Acad Sci U S A 2008;105(8):2993-8
75. Gattis JL, Washington AV, Chisholm MM, et al. The structure of the extracellular domain of triggering receptor expressed on myeloid cells like transcript-1 and evidence for a naturally occurring soluble fragment. J Biol Chem 2006;281(19):13396-403
76. Dowal L, Yang W, Freeman MR, et al. Proteomic analysis of palmitoylated platelet proteins. Blood 2011;118(13):e62-73
77. Morales J, Villa K, Gattis J, et al. Soluble TLT-1 modulates platelet-endothelial cell interactions and actin polymerization. Blood Coagul Fibrinolysis 2010;21(3):229-36
78. Barrow AD, Astoul E, Floto A, et al. Cutting edge: TREM-like transcript-1, a platelet immunoreceptor tyrosine-based inhibition motif encoding costimulatory immunoreceptor that enhances, rather than inhibits, calcium signaling via SHP-2. J Immunol 2004;172(10):5838-42
79. McVicar D, Washington A, Quigley L. inventors USA Govt Secretary of Dept Health and Human Services, assignee. TLT-1, a novel platelet-associated receptor and uses therefor. US20040180409A1; 2004
80. McVicar D, Washington A, Morales J. inventors USA Govt Secretary of Dept Health and Human Services, assignee. Soluble TREM-1 family peptides and methods of use. WO2010132370A8; 2010
81. Mori T, McVicar D. Giomarelli B. et al. Inventors USA Govt Secretary of Dept Health and Human Services, assignee. Anti-TREM-like transcript-1 (TLT-1) antibodies, methods and compositions. US20080131423A1; 2008
82. Kas K, Vanpoucke G. inventors Pronota NV, assignee. New biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof. US20110059858A1; 2011
83. Hilden I, Peschke B, Breinholt J, et al. inventors Novo Nordisk AS, assignee. Coagulation factor-targeting to TLT-1 on activated platelets. US20130337537A1; 2013
84. Gibot S, Derive M. inventors Institut National de la Sante et de la Recherche Medicale and Universite de Lorraine, assignee. Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof. US20130029921A1; 2013
85. Gibot S, Boufenzer A, Ait-Oufella H, et al. inventors Institut National de la Sante et de la Recherche Medicale and Universite de Lorraine, assignee. Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) trem-like transcript 1 (TLT-1) and uses thereof. WO2014037565A3; 2014
86. Derive M, Boufenzer A, Bouazza Y, et al. Effects of a TREM-like transcript 1-derived peptide during hypodynamic septic shock in pigs. Shock 2013;39(2):176-82
87. Derive M, Boufenzer A, Gibot S. Attenuation of responses to endotoxin by the triggering receptor expressed on myeloid cells-1 inhibitor LR12 in nonhuman primate. Anesthesiology 2014;120(4):935-42
88. Billadeau DD, Leibson PJ. ITAMs versus ITIMs: striking a balance during cell regulation. J Clin Invest 2002;109(2):161-8
89. Yoon SH, Lee YD, Ha J, et al. TLT-1s, alternative transcripts of triggering receptor expressed on myeloid cell-like transcript-1 (TLT-1), inhibits the triggering receptor expressed on myeloid cell-2 (TREM-2)-mediated signaling pathway during osteoclastogenesis. J Biol Chem 2012;287(35):29620-6
90. King RG, Herrin BR, Justement LB. Trem-like transcript 2 is expressed on cells of the myeloid/granuloid and B lymphoid lineage and is up-regulated in response to inflammation. J Immunol 2006;176(10):6012-21
91. Hashiguchi M, Kobori H, Ritprajak P, et al. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA 2008;105(30):10495-500
92. Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 2009;229(1):145-51
93. de Freitas A, Banerjee S, Xie N, et al. Identification of TLT2 as an engulfment receptor for apoptotic cells. J Immunol 2012;188(12):6381-8
94. Justement L, King R. inventors University of Alabama at Birmingham Research Foundation, assignee. Modulation of the innate immune system through the TREM-like transcript 2 protein. US20130216540A1; 2013
95. Cannon JP, O'Driscoll M, Litman GW. Specific lipid recognition is a general feature of CD300 and TREM molecules. Immunogenetics 2012;64(1):39-47
96. Bouchon A, Hernandez-Munain C, Cella M, et al. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 2001;194(8):1111-22
97. Su L, Liu C, Li C, et al. Dynamic Changes in Serum Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) and its Gene Polymorphisms are Associated with Sepsis Prognosis. Inflammation 2012;35(6):1833-43